Natera, Inc. $NTRA Shares Sold by Nwam LLC

Nwam LLC reduced its position in shares of Natera, Inc. (NASDAQ:NTRA) by 48.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,466 shares of the medical research company’s stock after selling 3,215 shares during the period. Nwam LLC’s holdings in Natera were worth $941,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Horizon Investments LLC increased its position in shares of Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after purchasing an additional 44 shares in the last quarter. Parallel Advisors LLC lifted its holdings in Natera by 5.5% in the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 47 shares in the last quarter. First Horizon Corp boosted its stake in Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after purchasing an additional 51 shares during the last quarter. Siemens Fonds Invest GmbH grew its holdings in shares of Natera by 3.1% during the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after buying an additional 54 shares in the last quarter. Finally, Alamea Verwaltungs GmbH grew its holdings in shares of Natera by 2.9% during the fourth quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock worth $515,000 after buying an additional 62 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Trading Up 1.4%

Natera stock opened at $325.17 on Thursday. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $343.18. The stock has a market cap of $46.87 billion, a P/E ratio of -239.09 and a beta of 1.54. The company has a 50-day moving average price of $289.96 and a 200 day moving average price of $236.14.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. Natera’s revenue was up 37.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.74) EPS. As a group, analysts forecast that Natera, Inc. will post -1.02 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NTRA. Wells Fargo & Company raised their price target on shares of Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. BTIG Research upped their price objective on shares of Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Royal Bank Of Canada increased their price objective on shares of Natera from $275.00 to $350.00 and gave the company an “outperform” rating in a report on Friday, August 7th. Sanford C. Bernstein started coverage on shares of Natera in a research note on Friday, June 26th. They issued an “outperform” rating and a $310.00 target price on the stock. Finally, Morgan Stanley restated an “overweight” rating and set a $355.00 target price on shares of Natera in a report on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $319.38.

Insider Buying and Selling

In other news, Director Gail Boxer Marcus sold 11,000 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the transaction, the director owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This represents a 64.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Herm Rosenman sold 16,530 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the transaction, the director owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. This represents a 79.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 62,348 shares of company stock valued at $15,870,496 in the last ninety days. Company insiders own 5.05% of the company’s stock.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.